Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
—·2h
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
TickersDMT, MDMAChannelsstocksCountriesusaCategoriesmergers-acquisitions
Open original source ↗Published
7/16/2026, 10:48:39 AM
Fetched
7/16/2026, 12:08:19 PM
Confidence
60 / 100
Relevance
44 / 100
Trust
—
Language
en